A next-generation pneumococcal conjugate vaccine, PCV20, a single-dose protection is now available in India marking a new ...

Pfizer has launched its 20-valent pneumococcal conjugate vaccine (PCV20) in India, offering single-dose protection against 20 ...

For decades, doctors have worked to protect people from Streptococcus pneumoniae, a bacterium responsible for pneumonia, ...

Pfizer’s PCV20 offers single-shot protection against 20 pneumococcal serotypes, safeguarding adults from serious respiratory ...

In a recent multicenter prospective study conducted at three hospitals in Tennessee and Georgia, including Vanderbilt ...

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

In a recent multicenter prospective study conducted at three hospitals in Tennessee and Georgia, including Vanderbilt University Medical Center ...

Among patients hospitalized with community-acquired pneumonia in Georgia and Tennessee, 14% had pneumococcal pneumonia.

Since the implementation of Streptococcus pneumoniae (SPn) conjugate vaccination (PCV), non-vaccine types have prevailed in invasive pneumococcal disease (IPD), and an increase in Staphylococcus ...

The "Pneumococcal Disease - Pipeline Insight, 2025" report offers in-depth analysis of over 20 drugs and 18 companies in the Pneumococcal Disease pipeline, covering clinical and nonclinical stages.

ADMA Biologics' recent Q2 report showed that the company is working on enhancing its plasma yields by over 20% in IG output.